Gevokizumab

Drug Profile

Gevokizumab

Alternative Names: S-78989; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Pyoderma; Uveitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Schnitzler syndrome; Scleritis
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Acne vulgaris; Osteoarthritis; Pyoderma

Most Recent Events

  • 09 Mar 2016 Servier terminates its licence for gevokizumab (XOMA, Form 10-K, March 2016)
  • 09 Mar 2016 XOMA plans to initiate a formal sales process for gevokizumab
  • 09 Mar 2016 Discontinued - Phase-III for Pyoderma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top